Policy Brief: Dr. Adam Leventhal Discusses the FDA Authorization of the Marketing of Three New E-Cigarette Products

<p>On this new Addiction Psychologist segment, we talk to experts about new policy developments to get a better understanding of the implications for our work, our clients, and our personal lives. On this episode, we talk with Dr. Adam Leventhal about the October 12, 2021 announcement that the FDA has <a href="https://www.fda.gov/tobacco-products/premarket-tobacco-product-applications/premarket-tobacco-product-marketing-granted-orders" title="Premarket Tobacco Product Marketing Granted Orders">a</a>uthorized the marketing of three new tobacco products, marking the first set of electronic nicotine delivery system (ENDS) products ever to be authorized by the FDA through the Premarket Tobacco Product Application (PMTA) pathway. Dr. Adam Leventhal is a Professor in the Department of Preventive Medicine and Psychology in the Keck School of Medicine at the University of Southern California and a member of the Tobacco Products Scientific Advisory Committee for the Food and Drug Administration.</p> <p>You can read the full FDA press release <a href="https://www.fda.gov/news-events/press-announcements/fda-permits-marketing-e-cigarette-products-marking-first-authorization-its-kind-agency">here</a>. In the days after the recording of this episode, the FDA made a similar announcement authorizing several oral tobacco products, suggesting that authorizations may occur at a rapid pace in the coming weeks.&nbsp;</p>